An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo.

Augmentation of nicotinic alpha7 receptor function is considered to be a potential therapeutic strategy aimed at ameliorating cognitive and mnemonic dysfunction in relation to debilitating pathological conditions, such as Alzheimer's disease and schizophrenia. In the present report, a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor (nAChR), 1-(5-chloro-2-hydroxy-phenyl)-3-(2-chloro-5-trifluoromethyl-phenyl)-urea (NS1738), is described. NS1738 was unable to displace or affect radioligand binding to the agonist binding site of nicotinic receptors, and it was devoid of effect when applied alone in electrophysiological paradigms. However, when applied in the presence of acetylcholine (ACh), NS1738 produced a marked increase in the current flowing through alpha7 nAChRs, as determined in both oocyte electrophysiology and patch-clamp recordings from mammalian cells. NS1738 acted by increasing the peak amplitude of ACh-evoked currents at all concentrations; thus, it increased the maximal efficacy of ACh. Oocyte experiments indicated an increase in ACh potency as well. NS1738 had only marginal effects on the desensitization kinetics of alpha7 nAChRs, as determined from patch-clamp studies of both transfected cells and cultured hippocampal neurons. NS1738 was modestly brain-penetrant, and it was demonstrated to counteract a (-)-scopolamine-induced deficit in acquisition of a water-maze learning task in rats. Moreover, NS1738 improved performance in the rat social recognition test to the same extent as (-)-nicotine, demonstrating that NS1738 is capable of producing cognitive enhancement in vivo. These data support the notion that alpha7 nAChR allosteric modulation may constitute a novel pharmacological principle for the treatment of cognitive dysfunction.

Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role.

BACKGROUND: The anticancer drug irinotecan induces cholinergic side effects that are currently ascribed to the blockade of acetylcholinesterase. This study investigated (1) the pattern of acetylcholinesterase activity in patients receiving treatment with irinotecan and (2) the relationship between acetylcholinesterase activity and plasma concentrations of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), and SN-38 glucuronide (SN-38G). METHODS: Twenty-five patients with advanced colorectal cancer were treated with 250 mg/m(2) irinotecan administered by intravenous infusion for 60 minutes. Blood samples were collected before drug infusion and at 15 minutes and 45 minutes after the start of drug infusion. Blood acetylcholinesterase activity was determined by a colorimetric enzymatic assay, and irinotecan, SN-38, and SN-38G concentrations were determined in plasma by HPLC. The in vitro effects of irinotecan and other drugs on human acetylcholinesterase were also assessed. RESULTS: Compared with basal values, the activity of acetylcholinesterase in blood specimens collected during irinotecan infusion at 15 minutes (-0.76%) and at 45 minutes (-1.50%) showed no changes. No relationships were established between the activity of blood acetylcholinesterase at 15 or 45 minutes and plasma concentrations of irinotecan, SN-38, or SN-38G measured at the same time points. In vitro, the activity of acetylcholinesterase was inhibited by 100-micromol/L irinotecan (-24.8%) and markedly reduced by 1-micromol/L physostigmine (-86.7%), whereas neither SN-38 nor camptothecin had an effect. CONCLUSIONS: Although the use of erythrocyte acetylcholinesterase as a surrogate marker of acetylcholinesterase activity in the nervous system has not been firmly established, our findings do not support the hypothesis that the toxic cholinergic syndrome associated with irinotecan treatment depends on acetylcholinesterase blockade.

Acute effect of nicotine on non-smokers: I. OAEs and ABRs.

This paper is the first in a series of three investigating the role of cholinergic mechanisms in the auditory system by assessing the acute effects of nicotine, an acetylcholinomimetic drug, on aggregate responses within the auditory pathway. In a single-blind procedure, auditory responses were obtained from 20 normal-hearing, non-smokers (10 male) under two conditions (nicotine, placebo). After the drug session, plasma tests revealed a subject's nicotine concentration. The effects of nicotine on early, exogenous responses of the auditory system (otoacoustic emissions and auditory brainstem potentials) are described in this first paper. Results indicated that transdermal administration of nicotine to non-smokers does not significantly affect cochlear activity but does acutely affect the neural transmission of acoustic information. Overall, otoacoustic emissions were unaffected by transdermal nicotine while wave I of the auditory brainstem response was significantly increased in latency and decreased in amplitude.

Acute effect of nicotine on non-smokers: II. MLRs and 40-Hz responses.

This paper is the second in a series of three investigating the role of cholinergic mechanisms in the auditory system by assessing the acute effects of nicotine, an acetylcholinomimetic drug, on aggregate responses within the auditory pathway. In a single-blind procedure, auditory responses were obtained from 20 normal-hearing, non-smokers (10 male) under two conditions (nicotine, placebo). The effects of nicotine on central, mesogenous responses of the auditory system (middle latency and 40-Hz responses) are described in this second paper. Results indicated that transdermal administration of nicotine to non-smokers does significantly affect the central, neural transmission of acoustic information. Na-Pa amplitude and Nb latency of the middle latency response and latency measures of the 40-Hz response were acutely altered by the presence of nicotine.

Acute effect of nicotine on non-smokers: III. LLRs and EEGs.

This paper is the last in a series of three investigating the role of cholinergic mechanisms in the auditory system by assessing the acute effects of nicotine, an acetylcholinomimetic drug, on aggregate responses within the auditory pathway. In a single-blind procedure, auditory responses were obtained from 20 normal-hearing, non-smokers (10 male) under two conditions (nicotine, placebo). The effects of nicotine on long-latency responses of the auditory system and on electroencephalograms are described in this paper. Results indicated that transdermal administration of nicotine to non-smokers significantly affects the afferent and efferent transmission of acoustic information, as well as enhancing cortical activation. Long-latency response amplitudes and electroencephalogram activity (dominant power and frequencies) were altered by acute doses of transdermal nicotine.

Prenatal nicotine sex-dependently alters agonist-induced locomotion and stereotypy.

This study examined the effects of prenatal nicotine exposure (2 mg/kg/day) via s.c. osmotic minipumps, gestational days 7-22, on nicotine- and lobeline-induced locomotor activity and stereotypy in 14-day-old rat pups. Prenatal nicotine exposure increased fetal mortality and produced decreases in weight gain apparent after weaning, but did not affect acquisition of developmental milestones. Compared to male pups prenatally exposed to saline, those prenatally exposed to nicotine and challenged with nicotine (1 mg/kg, i.p.) exhibited significantly greater locomotor activity, whereas a lobeline challenge (1 mg/kg, s.c.) produced significantly greater stereotypy. No effects of prenatal exposure were observed on locomotor activity or stereotypy in females. Results suggest that 1) central control of motor function may be more vulnerable to prenatal nicotine in males, and 2) nicotine and lobeline possess distinct pharmacological profiles.